Nanoscope Therapeutics reported positive outcomes from its Phase 2b RESTORE trial for MCO-010, aimed at treating retinitis pigmentosa.

The gene therapy MCO-010 demonstrated significant vision improvement in legally blind participants without serious side effects.

Both high and low doses of the therapy were more effective than a sham control in the trial.

Nanoscope intends to seek FDA approval with a Biologics License Application for MCO-010 in the latter half of 2024.

Positive interim results from a combined Phase 1/2 trial for MCO-010 have also been observed in treating both RP and Stargardt disease.

The company is developing another gene therapy, MCO-020, delivered by laser for age-related macular degeneration (AMD).

Nanoscope's MCO-010 platform could lead to a new paradigm in the treatment of inherited retinal diseases and AMD.